Repeats from Monday with no changes
** Shares of Johnson & Johnson JNJ.N rise 1% to $153.42 on Mon ahead of its first quarter results due before the market open on Tues with investors focused on how the pharmaceutical giant is dealing with tariffs imposed by President Donald Trump
** Trump announced a 90-day freeze on some of his new tariffs but left in place 10% tariffs on most U.S. imports
** Analysts expect JNJ to report rev of ~$21.57 bln, flat from a year ago, and EPS of $2.59, down ~4.5% from a year ago
** Among 26 analysts that cover JNJ, avg rating is "BUY" and median PT is $169.50, per LSEG data
** JNJ's rev has exceeded expectations 7 times over the last 8 quarters, while EPS has met estimates every time
** JNJ is up 6.4% YTD compared with the S&P 500 health index .SPXHC, which is up just ~6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.